Essentiale Forte Dosing for Mildly Elevated ALT and Gallbladder Polyp
The standard dose of Essentiale Forte (essential phospholipids) is 1800 mg per day, administered as 2 capsules (300 mg each) three times daily with meals. 1, 2
Standard Dosing Regimen
Initial intensive phase: 1800 mg/day (600 mg three times daily with meals) for 3–6 months to achieve maximal reduction in transaminases and improvement in hepatic steatosis 1, 2, 3
Maintenance phase: 900 mg/day after the initial 6 months to prevent relapse of liver enzyme elevations, though evidence shows that reducing the dose leads to relapse in 44–63% of patients 2
Each dose consists of 2 capsules of 300 mg taken with breakfast, lunch, and dinner to optimize absorption and maintain steady phospholipid levels throughout the day 1, 3
Rationale for This Patient
An ALT of 48 U/L is mildly elevated but does not contraindicate phospholipid therapy; in fact, studies demonstrate that Essentiale Forte reduces ALT by approximately 50–60% after 3 months of treatment 1, 2, 3
The 0.3 cm gallbladder polyp requires surveillance but not immediate intervention, as polyps <1 cm without high-risk features (age >60 years, sessile morphology, rapid growth) can be monitored with ultrasound every 6–12 months 4, 5
Essential phospholipids do not increase the risk of cholelithiasis or gallbladder complications and may be safely used in patients with small gallbladder polyps 2
Expected Clinical Response
ALT reduction of 50–60% within 3 months is the typical response, with parallel improvements in AST (approximately 46–75% reduction) 1, 3
Ultrasound improvement occurs in approximately 25–30% of patients, with normalization of hepatic steatosis in 5% and downgrading from grade II to grade I steatosis in 24% 2
Subjective symptoms (fatigue, right upper quadrant discomfort) improve in >95% of patients within the first 2–3 months of therapy 2, 3
Monitoring Strategy
Recheck ALT, AST, and lipid panel at 2–3 months to assess biochemical response and guide continuation of therapy 1, 2
Repeat abdominal ultrasound at 6 months to evaluate both hepatic steatosis and gallbladder polyp stability 2, 4
If ALT normalizes (<40 U/L) after 6 months, consider reducing to 900 mg/day, but be prepared to return to 1800 mg/day if transaminases rise again 2
Important Caveats
Do not discontinue therapy prematurely; stopping before 6 months or reducing the dose too early leads to relapse in the majority of patients 2
Essential phospholipids are a supportive adjunct, not a replacement for lifestyle modification; counsel the patient on weight loss (if BMI >25 kg/m²), Mediterranean or DASH dietary pattern, and ≥150 minutes/week of moderate-intensity aerobic exercise 6
The gallbladder polyp requires independent surveillance with ultrasound every 6–12 months; cholecystectomy is indicated only if the polyp grows to ≥1 cm, becomes symptomatic, or demonstrates high-risk features on imaging 4, 5
Essentiale Forte is generally well tolerated, with minimal gastrointestinal side effects reported in <5% of patients; no routine laboratory monitoring beyond transaminases is required 1, 2